The report “Global Anti-Venom Market, By Type (Monovalent and Polyvalent), By Animal Type (Snake, Scorpion, Spider and Others), By Distribution Channel (Hospital, Retail Pharmacies and Others), and Region - Global Forecast to 2030"
Anti-Venom Market accounted for US$ 2.60 billion in 2020 and is estimated to be US$ 4.70 billion by 2030 and is anticipated to register a CAGR of 6.1%.Global anti-venom market is driven owing to it is unique treatment option available for insect bites specifically for snake. Further, growing incidences of scorpion bites, snake bites, and other animal or insect bites such as fish stings also drives growth of the global anti-venom market.
Key Highlights:
· In 2018, Pfizer, Inc. worked with the U.S. Food and Drug Administration (FDA), to extend the expiration date of Antivenin’s Lot No. L67530 for an additional 12 months.
Before purchasing this report, request a sample or make an inquiry by clicking the following link:
https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/579
Key Market Insights from the report:
The Global Anti-Venom Market accounted for US$ 2.60 billion in 2020 and is estimated to be US$ 4.70 billion by 2030 and is anticipated to register a CAGR of 6.1%.The market report has been segmented on the basis of type, animal type, distribution channel, and region.
· By type, the global anti-venom market is segmented into monovalent and polyvalent.
· By animal type, the global anti-venom market is segmented into snake, scorpion, spider and others.
· By distribution channel, the global anti-venom market is segmented into hospital, retail pharmacies and others.
· By region, the North America region accounted major share in the global anti-venom market and is expected to retain its dominance over forecast period. This is attributed to the increasing incidences of scorpion bites and snake bites and rising expenditure on healthcare in North America region.
The prominent player operating in the global anti-venom market include Boston Scientific Corporation, CSL Limited, Pfizer, Inc., Merck & Co., Inc., Bharat Serums and Vaccines Limited, Haffkine Bio-Pharmaceutical Corporation Ltd., Vins Bioproducts Limited, Incepta Pharmaceuticals Ltd., Medline Industries Inc. and Rare Disease Therapeutics Inc.
